Clotixar 2,5 / 5 mg Film-coated tablets.
PDF Leaflet Revision Date: 18 December 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Prevention of VTE, stroke, and treatment of DVT/PE.
Dosage (summary)
2.5 mg twice daily for VTE prevention; 5 mg twice daily for NVAF; 10 mg twice daily for 7 days then 5 mg for DVT/PE.
Special Populations
- Renal impairment
- Hepatic impairment
- Elderly patients
Pregnancy & Breastfeeding
Not recommended during pregnancy; unknown if excreted in breast milk.
Key Drug Interactions
- Strong CYP3A4 and P-gp inhibitors
- Strong CYP3A4 and P-gp inducers
- Anticoagulants
Contraindications
- Hypersensitivity to apixaban
- Active bleeding
- Severe renal disease
- Severe hepatic impairment
Common side effects
- Haemorrhage
- Contusion
- Epistaxis
- Nausea
Counselling Points
- Take with or without food
- Monitor for signs of bleeding
- Do not stop abruptly before surgery
Serious warnings
- Risk of bleeding
- No reversal agent available
Important Disclaimer
The Clotixar 2,5 / 5 mg Film-coated tablets. professional information leaflet below is the property of Zydus Healthcare Sa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
